These findings demonstrate BC99’s capacity to attenuate multiple pathological pathways in allergic rhinitis (AR), including: IgA-mediated EOS activation and degranulation, Complement system activation via C3 reduction, and inflammatory cell recruitment through EOS suppression. This evidence concerns the gene C3 and allergic rhinitis.